Page last updated: 2024-12-05

glycocholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glycocholic acid is a bile acid synthesized in the liver from the primary bile acid cholic acid and the amino acid glycine. It is a major component of bile, which plays a crucial role in the digestion and absorption of fats. Glycocholic acid emulsifies fats in the small intestine, increasing their surface area and making them more accessible to digestive enzymes. This process is essential for the breakdown and absorption of dietary lipids. The study of glycocholic acid is important for understanding bile acid metabolism, the role of bile in digestion, and the potential impact of bile acid dysregulation on various health conditions. Research on glycocholic acid has focused on its role in cholesterol homeostasis, liver function, and gut health. For example, it has been shown to have a role in regulating cholesterol levels, preventing gallstone formation, and potentially influencing the composition of gut microbiota. Research continues to explore the complex interplay between glycocholic acid and other biological processes, shedding light on its potential therapeutic applications.'

Glycocholic Acid: The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycocholic acid : A bile acid glycine conjugate having cholic acid as the bile acid component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

glycocholate : A cholanic acid conjugate anion that is the conjugate base of glycocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID24856164
CHEMBL ID1434128
CHEBI ID182120
SCHEMBL ID60638
MeSH IDM0009454
PubMed CID10140
CHEMBL ID411070
CHEBI ID17687
SCHEMBL ID29022
MeSH IDM0009454

Synonyms (98)

Synonym
2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid;hydrate
CHEBI:182120
glycocholic acid hydrate
glycocholic acid hydrate, synthetic, >=97% (hplc)
smr000718746
MLS001304001 ,
HMS2230A24
1192657-83-2
AKOS025310113
SCHEMBL60638
CHEMBL1434128
mfcd06408004
DTXSID10647723
glycocholic acid (hydrate)
F82449
BIDD:PXR0160
smr001233215
MLS002153857
BRD-K54771420-001-03-2
CHEBI:17687 ,
n-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oyl)glycine
n-[(3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
SPECTRUM5_002011
PRESTWICK_768
cas-475-31-0
PRESTWICK2_000521
LMST05030001
n-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oyl)-glycine
cholylglycine
BSPBIO_000501
PRESTWICK3_000521
glycine, n-choloyl-
glycine, n-[(3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl]-
GCH ,
glycine, n-((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl)-
3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oylglycine
glycocholate
C01921
glycocholic acid
475-31-0
PRESTWICK1_000521
PRESTWICK0_000521
SPBIO_002422
BPBIO1_000553
NCGC00163115-02
glycocholic acid, free acid
G-5270
CHEMBL411070 ,
BMSE000651
HMS1569J03
HMS2096J03
einecs 207-494-9
unii-g59nx3i3rt
n-((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl)glycine
n-(carboxymethyl)-3alpha,7alpha,12alpha-trihydroxyglycine cholate
g59nx3i3rt ,
n-(3-alpha,7-alpha,12-alpha-trihydroxycholan-24-oyl)glycine
NCGC00256646-01
tox21_302549
dtxsid2047436 ,
dtxcid0027436
A827264
((r)-4-((3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycine;glycocholic acid
HMS2231A05
AKOS015965042
bdbm50375589
glycocholic acid [who-dd]
glycocholic acid [mi]
S4958
2-[(4r)-4-[(1s,2s,5r,7s,9r,10r,11s,14r,15r,16s)-5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]acetic acid
gtpl4544
SCHEMBL29022
3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid n-(carboxymethyl)amide
DS-0968
[(3,7,12-trihydroxy-24-oxocholan-24-yl)amino]acetic acid #
RFDAIACWWDREDC-FRVQLJSFSA-N
glycine, n-[(3a,5b,7a,12a)-3,7,12-trihydroxy-24-oxocholan-24-yl]-
CS-W020037
2-((r)-4-((3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)acetic acid
AC-30905
mfcd00065902
2-[(4r)-4-[(1s,2s,5r,7s,9r,10r,11s,14r,15r,16s)-5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0?,?.0??,??]heptadecan-14-yl]pentanamido]acetic acid
n-choloyl-glycine
glycylcholic acid
n-(carboxymethyl)-3a,7a,12a-trihydroxy-5b-cholan-24-amide
glycylcholate
3a,7a,12a-trihydroxy-5b-cholan-24-oylglycine
3a,7a,12a-trihydroxy-5b-cholanic acid-24-glycine
3a,7a,12a-trihydroxy-n-(carboxymethyl)-5b-cholan-24-amide
glycoreductodehydrocholic acid
HY-N1423
n-[(3beta,5beta,7beta,9beta,12beta)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
5beta-cholanic acid-3alpha,7alpha,12alpha-triol n-(carboxymethyl)-amide
Q2701638
n-[(3alpha,5beta,7alpha,8xi,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
STL565148
CCG-269413
((r)-4-((3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycine

Research Excerpts

Overview

Glycocholic acid (GCA) is a newly identified biomarker for hepatocellular carcinoma (HCC) patients.

ExcerptReferenceRelevance
"Glycocholic acid (GCA) is a newly identified biomarker for hepatocellular carcinoma (HCC) patients. "( Macromolecular Crowding Agents-Assisted Imprinted Polymers For Analysis Of Glycocholic Acid In Human Plasma And Urine.
Ge, CQ; Li, QF; Zhan, YM; Zhang, B; Zhong, YG, 2016
)
2.11

Effects

ExcerptReferenceRelevance
"Glycocholic acid (GCA) has been identified as a novel selective and sensitive biomarker for hepatocellular carcinoma (HCC). "( Biotinylated single-chain variable fragment-based enzyme-linked immunosorbent assay for glycocholic acid.
Barnych, B; Cui, X; Hammock, BD; He, Q; Jiang, Z; Shen, D; Vasylieva, N; Yang, J; Zhao, S, 2018
)
2.15

Toxicity

ExcerptReferenceRelevance
" The coupling of cell colonies with a suitable transduction device has led to the development in recent years of toxicity biosensors based on the alteration of a process or a cell metabolic function by the toxic substance under examination."( Toxicity order of cholanic acids using an immobilised cell biosensor.
Campanella, L; Favero, G; Mastrofini, D; Tomassetti, M, 1996
)
0.29
"We studied the enhancing and toxic effects of five different absorption enhancers on the transport of FITC-dextran with an average molecular weight of 4000 (FD-4) across Caco-2 cell monolayers, and their enhancing effects were also compared with those in rat intestine."( Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers.
Fujita, T; Hattori, K; Lundborg, E; Murakami, M; Muranishi, S; Quan, YS; Yamamoto, A, 1998
)
0.3
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profile for the microemulsion showed rapid distribution and elimination compared to Diprivan(®)."( A propofol microemulsion with low free propofol in the aqueous phase: formulation, physicochemical characterization, stability and pharmacokinetics.
Cai, W; Chen, X; Deng, W; Jin, F; Yang, H, 2012
)
0.38
" The physical compatibility, pharmacokinetic, and vascular irritability studies showed that, in comparison to the commercially available NIM injections, NIM-EPC-SGC-MMs presented better physical compatibility, the same pharmacokinetic profile, and less risk of local vascular irritation and phlebitis."( Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study.
Gong, T; Jiang, Y; Ren, C; Song, X; Sun, X; Zhang, Q; Zhang, Z, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" The rate of absorption decreased from the colon to the duodenum (colon greater than ileum greater than jejunum greater than duodenum)."( Intestinal oxalate absorption. I. Absorption in vitro.
Caspary, WF, 1977
)
0.26
" With regard to GHRH and CRH, previous studies demonstrated that their bioavailability following in administration was very low."( Effect of intranasal growth hormone-releasing hormone and corticotropin-releasing hormone administration on growth hormone and cortisol release: improved bioavailability by means of sodium-glycocholate.
Fattor, B; Perfetti, MG; Pontiroli, AE; Pozza, G, 1989
)
0.28
" The systemic bioavailability of insulin calculated from its area under concentration-time curve was in good agreement with that derived from the glucose concentration-time curve."( The ocular route for systemic insulin delivery in the albino rabbit.
Dodda-Kashi, S; Lee, VH; Luo, AM; Yamamoto, A, 1989
)
0.28
" Bioavailability of this nasal formulation relative to a single subcutaneous dose averaged 21%."( Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.
Anik, S; Chan, RL; Chaplin, MD; Henzl, MR; LaFargue, J; LePage, ME; Nerenberg, CA, 1988
)
0.27
"Intranasal insulin is effective in raising serum insulin (IRI) levels and lowering blood glucose levels in normal subjects and in diabetics, but its bioavailability is low."( Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavailability and effectiveness in normal subjects.
Alberetto, M; Calderara, A; Pajetta, E; Pontiroli, AE; Pozza, G,
)
0.13
" Further studies are needed to improve bioavailability and efficacy of intranasally administered glucagon."( Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection.
Alberetto, M; Pontiroli, AE; Pozza, G,
)
0.13
" Bropirimine in solution was well absorbed in the overall small intestine, following first-order kinetics."( Small intestinal absorption of bropirimine in rats and effect of bile salt on the absorption.
Emori, H; Nishihata, T; Yokohama, S, 1995
)
0.29
" Thus, the increased subcutaneous bioavailability of hEGF in the presence of absorption promoters (except EDTA) was mainly attributed to the inhibitory effect of absorption promoters against the enzymic degradation of hEGF at the subcutaneous tissues."( Effect of absorption promoters on subcutaneous absorption of human epidermal growth factor in rats.
Amagase, H; Fuwa, T; Higashi, Y; Kojima, Y; Misaki, M; Murakami, T; Yamada, M; Yata, N; Yuki, M, 1993
)
0.29
" The apparent nasal absorption rate constants of acyclovir and its butyrate, valerate, pivalate, and hexanoate ester prodrugs in mixed micellar solutions containing an esterase inhibitor (1 mM phenylmethylsulfonyl fluoride) were individually calculated."( Bile salt-fatty acid mixed micelles as nasal absorption promoters. III. Effects on nasal transport and enzymatic degradation of acyclovir prodrugs.
Mitra, AK; Shao, Z, 1994
)
0.29
" The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution."( Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24).
Buri, P; Martenet, M; Wüthrich, P, 1994
)
0.29
" An alternative approach is to measure the hepatic metabolism of a highly extracted compound whose oral clearance and systemic bioavailability are dependent on both hepatocyte function and degree of portosystemic shunt."( Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis.
Adedoyin, A; Arns, PA; Branch, RA; DiBisceglie, AM; Hoofnagle, JH; Waggoner, JG; Wilkinson, GR, 1997
)
0.3
" The use of a penetration enhancer is required to improve the bioavailability of the drug via buccal route."( In vitro studies on enhancing effect of sodium glycocholate on transbuccal permeation of morphine hydrochloride.
Capan, Y; Duchêne, D; Hincal, AA; Ponchel, G; Senel, S, 1998
)
0.3
"Pulmonary drug administration of most peptide/protein drugs is characterized by low bioavailability due to low permeability."( Histopathological study of the effects of a single intratracheal instillation of surface active agents on lung in rats.
Adachi, K; Awazu, S; Hayashi, M; Machida, M; Otabe, K; Sugimoto, T; Suzuki, M, 2000
)
0.31
"The aim of the present study was to investigate the absolute nasal bioavailability of Peptide T from aqueous formulations containing sodium glycocholate, an absorption enhancer with known effect on epithelial tight junctions, and/or glycofurol in a crossover study in rabbits."( Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol.
Bagger, MA; Bechgaard, E; Nielsen, HW, 2001
)
0.31
" In order to improve the absorption rate of insulin into systemic circulations, the effects of pH and absorption enhancers were studied with rabbit eyes."( Alternative delivery of insulin via eye drops.
Chiou, GC; McClellan, DA; Moore, R; Xuan, B, 2005
)
0.33
"To develop a stable micellar formulation of vitamin K for oral delivery, because the commercial and clinically used formulation of vitamin K (Konakion® MM) destabilizes at gastric pH resulting in low bioavailability of this vitamin in neonates with cholestasis."( A Mixed Micelle Formulation for Oral Delivery of Vitamin K.
Hennink, WE; Jaspers, TC; Sun, F; van Hasselt, PM; van Nostrum, CF, 2016
)
0.43
" The relative bioavailability and pharmacological availability of such a formulation, as determined vs."( In vitro and in vivo evaluation of an oral multiple-unit formulation for colonic delivery of insulin.
Caliceti, P; Del Curto, MD; Gazzaniga, A; Maroni, A; Melocchi, A; Salmaso, S; Zema, L, 2016
)
0.43
"The chief objective of this research was to appraise liposomes embodying a bile salt, sodium glycocholate (SGC), as oral nanoscale drug delivery system to strengthen the bioavailability of a water-soluble and weakly penetrable pharmaceutical, notoginsenoside R1 (NGR1)."( Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo.
Fan, Q; Feng, N; Hou, X; Li, Z; Shao, Q; Zhang, K; Zhang, Y, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
"Analysis of a modified 14C-glycocholate breath test on 165 consecutive in-patients being investigated for chronic diarrhea showed that the measurement of 14CO2 between 3 and 6 h after oral dosing of 5 microCi of 14C-glycocholic acid was of only limited use to distinguish between patients with Crohn's disease (CD), idiopathic bile salt wastage (IBW), or ileal resection (IR) from those with the irritable bowel syndrome (IBS)."( Limitations in the use of 14C-glycocholate breath and stool bile acid determinations in patients with chronic diarrhea.
Ferguson, J; Thomson, AB; Walker, K, 1986
)
0.46
" Serum chemistries and immunologic parameters of guinea pigs dosed twice were less conclusive, as neither high nor low doses differed from guinea pigs treated once."( Effects of pre-treatment with aflatoxin on a second aflatoxin treatment in guinea pigs.
Peden, WM; Richard, JL; Sacks, JL; Thurston, JR, 1987
)
0.27
" Activities of AST in treated guinea pigs were significantly higher than those in controls for only 2 dosage levels (0."( Serum concentration of bile acids in guinea pigs as an indicator of liver damage caused by aflatoxins.
Baetz, AL; McLoughlin, ME, 1983
)
0.27
" The rate determining step for the disappearance of bropirimine from the small intestinal loop after dosing in the suspension was the dissolution process from suspension."( Small intestinal absorption of bropirimine in rats and effect of bile salt on the absorption.
Emori, H; Nishihata, T; Yokohama, S, 1995
)
0.29
" Placing physiologic limits on values of GC* and Cl* suggests requisite selectivity properties of more potent bile acid sequestrants and dosing strategies to optimize current resin therapy."( Mathematical model and dimensional analysis of glycocholate binding to cholestyramine resin: implications for in vivo resin performance.
Amidon, GL; Polli, JE, 1995
)
0.29
" The primary goal was to investigate the effect of cholate type, particle size and dosage of the liposomes on the hypoglycemic activity and oral bioavailability."( Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose.
Guan, P; Hovgaard, L; Lian, R; Lu, Y; Niu, M; Qi, J; Tan, Y; Wu, W, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bile acid glycine conjugateAmide of a bile acid with glycine.
bile acid glycine conjugateAmide of a bile acid with glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Disorders of bile acid synthesis and biliary transport1840
Drug induction of bile acid pathway025
Biochemical pathways: part I0466
Glucose homeostasis021

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency31.62280.044717.8581100.0000AID485341
ATAD5 protein, partialHomo sapiens (human)Potency0.46090.004110.890331.5287AID504467
importin subunit beta-1 isoform 1Homo sapiens (human)Potency0.20605.804836.130665.1308AID540253
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
snurportin-1Homo sapiens (human)Potency0.20605.804836.130665.1308AID540253
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency50.11870.010323.856763.0957AID2662
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency0.20605.804816.996225.9290AID540253
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
Guanine nucleotide-binding protein GHomo sapiens (human)Potency28.18381.995325.532750.1187AID624288
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.81840.044717.8581100.0000AID485294
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.53030.000229.305416,493.5996AID743079
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.07380.001723.839378.1014AID743083
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency43.81270.000323.4451159.6830AID743065; AID743066; AID743067
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)400.00000.20005.677410.0000AID681389
Bile salt export pumpHomo sapiens (human)Ki11.00007.00008.25009.5000AID679472
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)13.60000.02372.52598.9000AID324923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A5Rattus norvegicus (Norway rat)Km15.40004.30006.39608.8000AID681360
Bile salt export pumpHomo sapiens (human)Km11.10004.25004.52504.8000AID680159
Sodium/bile acid cotransporterRattus norvegicus (Norway rat)Km27.00003.70005.36677.4000AID679119
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Km54.00000.01503.49967.0000AID682135
Bile salt export pumpMus musculus (house mouse)Km19.50005.70005.70005.7000AID681654
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID681389TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells2003The Biochemical journal, Apr-15, Volume: 371, Issue:Pt 2
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4).
AID682213TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM, GC: 200 uM) in membrane vesicles isolated from Mrp3-expressing LLC-PK1 cells2000The Journal of biological chemistry, Jan-28, Volume: 275, Issue:4
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).
AID681352TP_TRANSPORTER: transepithelial transport (basal to apical) in Ntcp/Bsep double transfected MDCK cell2005American journal of physiology. Gastrointestinal and liver physiology, Jan, Volume: 288, Issue:1
Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID678824TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Gastroenterology, Feb, Volume: 120, Issue:2
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.
AID680636TP_TRANSPORTER: inhibition of BSP uptake (BSP: 2 uM, GC: 100 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID681361TP_TRANSPORTER: uptake in Oatp3-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID679139TP_TRANSPORTER: uptake in membrane vesicles from LLC-PK1 cells2000The Journal of biological chemistry, Jan-28, Volume: 275, Issue:4
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).
AID682103TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, GC: 300 uM) in membrane vesicles from MRP3-expressing HEK293 cells2001Cancer research, Oct-01, Volume: 61, Issue:19
Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
AID682094TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 20 uM, GC: 200 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID681135TP_TRANSPORTER: uptake in OATP-F-expressing CHO cells2002Molecular endocrinology (Baltimore, Md.), Oct, Volume: 16, Issue:10
Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID681654TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells2001Hepatology (Baltimore, Md.), May, Volume: 33, Issue:5
Characterization of the mouse bile salt export pump overexpressed in the baculovirus system.
AID682135TP_TRANSPORTER: uptake in Oatp1-expressing CHO-03 cell1999The American journal of physiology, 04, Volume: 276, Issue:4
Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells.
AID680225TP_TRANSPORTER: uptake of Glycocholate at 20 u M in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID680159TP_TRANSPORTER: uptake in membrane vesicles isolated from Bsep-expressing Sf9 cells2002Gastroenterology, Nov, Volume: 123, Issue:5
Functional expression of the canalicular bile salt export pump of human liver.
AID682188TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 1.2 uM, GC: 50 uM) in membrane vesicles isolated from Mrp3-expressing LLC-PK1 cells2000The Journal of biological chemistry, Jan-28, Volume: 275, Issue:4
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).
AID681136TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells1999Molecular pharmacology, Apr, Volume: 55, Issue:4
Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID679711TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.72 uM, GC: a 100-fold excess) in isolated mouse ileocytes1999Journal of biochemistry, Apr, Volume: 125, Issue:4
Characterization, cDNA cloning, and functional expression of mouse ileal sodium-dependent bile acid transporter.
AID680590TP_TRANSPORTER: inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 uM, GC: 500.0 uM) in membrane vesicles from MRP3-expressing Sf9 cells2003The Biochemical journal, Jan-01, Volume: 369, Issue:Pt 1
Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.
AID681552TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 10 uM, GC: 100 uM) in Ntcp-expressing HPCT-1E3 cells1996European journal of cell biology, May, Volume: 70, Issue:1
Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts.
AID679138TP_TRANSPORTER: uptake in membrane vesicles isolated from Mrp3-expressing LLC-PK1 cells2000The Journal of biological chemistry, Jan-28, Volume: 275, Issue:4
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).
AID681360TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID681896TP_TRANSPORTER: inhibition of Taurocholate uptake in the presence of Glycocholate at a concentration of 20uM in membrane vesicles from MRP4-expressing V79 cells2003Hepatology (Baltimore, Md.), Aug, Volume: 38, Issue:2
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
AID682018TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.72 uM, GC: 72 uM) in Ntcp-expressing COS-7 cells2002Bioscience, biotechnology, and biochemistry, May, Volume: 66, Issue:5
Characterization of cloned mouse Na+/taurocholate cotransporting polypeptide by transient expression in COS-7 cells.
AID681602TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997Hepatology (Baltimore, Md.), Dec, Volume: 26, Issue:6
Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID681530TP_TRANSPORTER: uptake of Glycocholate at a concentration of 4 u M in NTCP-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID679119TP_TRANSPORTER: uptake in Ntcp-expressing CHO cells1998The American journal of physiology, 02, Volume: 274, Issue:2
Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells.
AID657096Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 100 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scin2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID680036TP_TRANSPORTER: inhibition of BSP uptake (BSP: 10 uM, GC: 100 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID682047TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, Glycocholate: 100uM) in membrane vesicles from MRP7-expressing HEK293 cells2003Molecular pharmacology, Feb, Volume: 63, Issue:2
Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
AID678958TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Gastroenterology, Feb, Volume: 120, Issue:2
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.
AID678812TP_TRANSPORTER: uptake in membrane vesicles from MRP3-expressing HEK293 cells2000Cancer research, Sep-01, Volume: 60, Issue:17
Transport of amphipathic anions by human multidrug resistance protein 3.
AID680591TP_TRANSPORTER: inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 uM, GC: 500 uM) by Glycocholate at a concentration of 500uM in membrane vesicle from MRP3-expressing Sf9 cells2003The Biochemical journal, Jan-01, Volume: 369, Issue:Pt 1
Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.
AID680612TP_TRANSPORTER: inhibition of Estradiol-17beta-D-glucuronide uptake by Glycocholate at a concentration of 10 uM in membrane vesicle from MRP8-expressing LLC-PK1 cells2005Molecular pharmacology, Feb, Volume: 67, Issue:2
Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11).
AID682214TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM, GC: 200 uM) in membrane vesicles from LLC-PK1 cells2000The Journal of biological chemistry, Jan-28, Volume: 275, Issue:4
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).
AID681151TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Gastroenterology, Feb, Volume: 120, Issue:2
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.
AID680003TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, GC: 200 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID678843TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells2000Gastroenterology, Feb, Volume: 118, Issue:2
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
AID679573TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, GC: 100 uM) in Xenopus laevis oocytes1994The Journal of clinical investigation, Mar, Volume: 93, Issue:3
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.
AID682191TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 1.2 uM, CA: 500 uM) in membrane vesicles from LLC-PK1 cells2000The Journal of biological chemistry, Jan-28, Volume: 275, Issue:4
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).
AID680224TP_TRANSPORTER: uptake of Glycocholate at 4 u M in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID681346TP_TRANSPORTER: ATP-dependent uptake in membrane vesicle from MRP8-expressing LLC-PK1 cells2005Molecular pharmacology, Feb, Volume: 67, Issue:2
Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11).
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID680246TP_TRANSPORTER: uptake in Oatp1-expressing CHO-03 cell2003Biochimica et biophysica acta, Apr-01, Volume: 1611, Issue:1-2
Sensitivity of bile acid transport by organic anion-transporting polypeptides to intracellular pH.
AID680451TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, GC: 100uM) in Xenopus laevis oocytes1996The Journal of pharmacology and experimental therapeutics, Dec, Volume: 279, Issue:3
Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide.
AID679338TP_TRANSPORTER: uptake in Ntcp-expressing HPCT-1E3 cells1996European journal of cell biology, May, Volume: 70, Issue:1
Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts.
AID681349TP_TRANSPORTER: uptake in ASBT-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID679472TP_TRANSPORTER: competitive inhibition of Taurocholate uptake in membrane vesicles prepared from High Five cells infected with the ABCB11 baculovirus2002Gastroenterology, Nov, Volume: 123, Issue:5
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (777)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990427 (54.95)18.7374
1990's148 (19.05)18.2507
2000's94 (12.10)29.6817
2010's70 (9.01)24.3611
2020's38 (4.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.82 (24.57)
Research Supply Index6.73 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index107.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials17 (2.07%)5.53%
Reviews0 (0.00%)6.00%
Reviews13 (1.58%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies5 (0.61%)4.05%
Observational0 (0.00%)0.25%
Observational1 (0.12%)0.25%
Other5 (100.00%)84.16%
Other785 (95.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Conjugated Cholic Acid for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-Chain Conjugation [NCT01589523]Phase 35 participants (Actual)Interventional2006-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01589523 (5) [back to overview]Conjugated Cholic Acid (GCA) for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-chain Conjugation.
NCT01589523 (5) [back to overview]Change in Liver Function Test: AST From Baseline to Post-treatment
NCT01589523 (5) [back to overview]Change in Vitamin D, 25-OH Measure From Baseline to Post-treatment
NCT01589523 (5) [back to overview]Changes in Liver Function Tests of ALT From Baseline to Post-treatment
NCT01589523 (5) [back to overview]Evaluation of Levels of Atypical Bile Acid Metabolites After GCA Treatment Compared

Conjugated Cholic Acid (GCA) for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-chain Conjugation.

This is the number of participants with bile acid amidation defects treated with oral glycocholic acid (15 milligrams/kilograms (mg/kg) of body weight/day (bw/day)) (NCT01589523)
Timeframe: Up to 10 years

InterventionParticipants (Count of Participants)
15 mg/Kg Body Weight/Day5

[back to top]

Change in Liver Function Test: AST From Baseline to Post-treatment

Measure of Aspartate Aminotransferase (AST) (NCT01589523)
Timeframe: Comparison between baseline and post-treatment (average of available timepoints after year 1 through year 10)

Interventionunits per liter (U/L) (Median)
Baselineaverage of available timepoints after year 1 through year 10
Glycocholic Acid6539

[back to top]

Change in Vitamin D, 25-OH Measure From Baseline to Post-treatment

Measure Vitamin D levels nanograms per milliliter (ng/mL) (NCT01589523)
Timeframe: Pre-treatment and post treatment (average of available timepoints after year 1 through year 10)

Interventionnanograms per milliliter (ng/mL) (Mean)
Baselineaverage of available timepoints after year 1 through year 10
Glycocholic Acid1.025.7

[back to top]

Changes in Liver Function Tests of ALT From Baseline to Post-treatment

Liver function tests Alanine Aminotransferease (ALT) (NCT01589523)
Timeframe: Comparison between baseline and post-treatment (average of available timepoints after year 1 through year 10)

Interventionunits per liter (U/L) (Mean)
Baselineaverage of available timepoints after year 1 through year 10
Glycocholic Acid43.831.7

[back to top]

Evaluation of Levels of Atypical Bile Acid Metabolites After GCA Treatment Compared

Semi-quantitative descriptive evaluation of the levels of atypical bile acids in urine measured by mass spectrometry (FAB MS) based on a scale of 0 = absent or traces levels, 1 = low levels, 2 = moderate levels, 3 = high levels using the signal/noise ratio and intensity of ions. Atypical bile acids evaluated included m/z 407 (unconjugated cholic acid), m/z 471 (dihydroxy-choleanoic-sulfate) and m/z 583 (trihydroxy-choleanoic glucuronide). (NCT01589523)
Timeframe: Average of 6 months, average 12 months, and average of after year 1 to 10 years

Interventionscore on a scale (Median)
6 months average12 months averageaverage of year 1 to 10
10-15 mg/Kg Body Weight/Day1.411

[back to top]